长春高新子公司GenSci145片临床试验获批准

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial of GenSci145 tablets, a new selective PI3Kα inhibitor for treating advanced or metastatic solid tumors with PIK3CA mutations [1]. Group 1 - Changchun Jinsai Pharmaceutical has developed GenSci145 tablets, classified as a first-class innovative chemical drug [1]. - The drug is intended for patients with locally advanced or metastatic solid tumors carrying PIK3CA mutations [1].